期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性肾脏病合理应用活性维生素D及专家共识 被引量：7

原文传递
导出
摘要 慢性肾脏病（CKD）患者普遍存在矿物质和骨代谢紊乱，2005年KDIGO将其定义为：慢性肾脏病相关性矿物质及骨代谢紊乱（CKD—MBD），可表现为钙、磷、甲状旁腺激素（PTH）或维生素D代谢异常，骨转化、矿化、骨容量、骨骼线性生长或骨强度的异常，还可表现为血管或其他软组织钙化。有研究显示，慢性肾脏病患者早期即出现维生素D的减少及矿物质和骨代谢紊乱，并贯穿于肾功能进行性减退的全过程，
作者 江建青
机构地区 天津医科大学总医院肾内科
出处 《临床内科杂志》 CAS 2012年第5期299-301,共3页 Journal of Clinical Internal Medicine
关键词 慢性肾脏病 活性维生素D
分类号 R692 [医药卫生—泌尿科学]
  • 相关文献

参考文献21

  • 1钱莹,陈楠.骨保护素和肾性骨病[J].中国实用内科杂志,2004,24(7):444-445. 被引量：12
  • 2Subhashini Yaturu, Jared Davis. Prevalence of Decreased Vitamin D Levels is high among Veterans with Diabetes and/or CKD. ISRN Endocrinology Volume,2011 ,Article ID: 109458.
  • 3Reynolds JL, Joannides A J, Skeper JA, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol,2004,15:2857-2867.
  • 4Wang AY, Woo J, Lam CW, et al. Associations of serum fetuin-a with malnutrition, inflammation, atherosclerosis and vascular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant,2005,20 : 1676-1685.
  • 5Wang TJ, Pencina M J, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation,2008,117:503-511.
  • 6Fishbane S, Chittineni H, Packman M, et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria:A randomized trial. Am J Kidney Dis,2009,54:647-652.
  • 7Alborzi P, Pate1 NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease:A randomized doubleblind pilot trial. Hypertension, 2008,52 : 249 -255.
  • 8Shoben AB, Rudser KD, de Boer IH, et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol,2008, 19:1613-1619.
  • 9Kovesdy CP, Ahmadzadeh S, Anderson JE, et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med ,2008,168:397-403.
  • 10廖二元.维生素D制剂的药理机制与临床应用[J].中南药学,2003,1(2):98-102. 被引量：12

二级参考文献21

  • 1[1]Mawer EB,Davis M.Vitamin D nutrition and bone disease in adults[J].Rev Endocr Metab Disord,2001,2(2):153
  • 2[2]Bouillon R,Okamura WH,Norman AW.Structure-function relationships in the vitamin D endocrine system[J].Endocr Rev,1995,16:200
  • 3[3]Van Leeuwen JP,Vanden Bend GJ,Van Driel M,et al.24-25-dihydroxyvitamin D and bone metabolism[J].Steroids,2001,66(3～5):375
  • 4[4]Beckman MJ,DeLuca HF.Regulation of renal vitamin D receptor is an important determinant of 1alpha,25-dihydroxyvitamin D3 levels in vivo[J].Arch Biochem Biophys,2002,401(1):44
  • 5[5]Siaw EK,Walters WR.1,25-dihydroxyvitamin D-stimulated calmodulin binding proteins:a sustained effect on distal tubules[J].Am J Physiol Renal Physiol,2002,282(1):F77
  • 6[6]Aschenbrenner JK,Sollinger HW,Becker BN,et al.1α,25-(OH)2D3 alters the transforming growth factor beta signaling pathway in renal tissue[J].J Surg Res,2001,100(2):171
  • 7[7]Funahashi H,Tanaka Y,Imai T,et al.Parathyroid hormone suppression by 22-oxacalcitriol in the severe parathyroid hyperplasia[J].J Endocrinol Invest,1998,21(1):43
  • 8[8]Dusso AS,Pavlopoulos T,Naumovich L,et al.P21(WAF1)and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth[J].Kidney Int,2001,59(3):855
  • 9[9]Kveiborg M,Rattan SI,Clark BF,et al.Treatment with 1,25-dihydroxyvitamin D3 reduces impairment of human osteoblast functions during cellular aging in culture[J].J Cell Physiol,2001,186(2):298
  • 10[10]Janssen HC,Samson MM,Verhaar HJ.Vitamin D deficiency,muscle function,and falls in elderly people[J].Am J Clin Nutr,2002,75(4):611

共引文献117

同被引文献69

  • 1姜鸿,徐志宏,张凌,宋韩明,李文歌.慢性肾脏病3～5期透析前患者矿物质及骨代谢紊乱的调查分析[J].中国血液净化,2012,11(7):360-364. 被引量：43
  • 2王海燕.肾脏病学[M].3版.北京:人民卫生出版社,2008:8262.
  • 3王质刚.血液净化学[M].北京：北京科学技术出版社,1992.199-213.
  • 4Bolasco P.Effects of the use of non-calcium phosphate binders in the control and outcome of vascular calcifications: A review of clinical trials on CKD patients [J].Int J Nephrol, 2011, 2011: 758450.
  • 5Fukagawa M, Kurokawa K.Pathogenesis and medical treatment of secondary hyperparathyroidism[J].Semin Surg Oncol, 1997, 13(2): 73-77.
  • 6Mittman N, Desiraju B, Meyer KB.Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study[J].Kidney Int Suppl, 2010(117): S33-36.
  • 7Souqiyyeh MZ, Shaheen FA.Survey of attitudes of Physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder(CKD-MBD) [J].Saudi J Kidney Dis Transpl, 2010, 21(1): 93-101.
  • 8Fukagawa M, Komaba H, Onishi Y.Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: Baseline data from the MBD-5D [J].Am J Nephrol, 2011, 33(5): 427-437.
  • 9Moranne O, Froissart M, Rossert J.Timing of onset of CKD-related metabolic complications [J].J Am Soc Nephrol, 2009, 20(1): 164-171.
  • 10Meola M, Petrucci I, Cupisti A.Ultrasound in clinical setting of secondary hyperparathyroidism [J].J Nephrol, 2012[Epub ahead of print].

引证文献7

二级引证文献35

临床内科杂志
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部